BGES Bio Bridge Science Inc (CE)

Bio-Bridge-Science Inc. (BGES.OB) announced that CEO Dr. Liang Qiao is featured in an interview with the Wall Street Reporter Senior Analyst Ian Roberts. The topics of discussion include the company's unique technology platform and its promising new HIV vaccine. Dr. Qiao also elaborates upon Bio-Bridge Science's plans and prospects for the upcoming year. The interview is available now on www.wallstreetreporter.com and can be accessed through the 'Interviews A thru Z link' under Bio-Bridge Science. About Bio-Bridge Science: Bio-Bridge Science is a biotechnology firm focused on the development of vaccines with broad therapeutic and preventive applications. Through its wholly owned subsidiary in Beijing, Bio-Bridge is developing a promising new HIV Vaccine, that is expected to enter clinical trials early next year in China. The vaccine, based on exclusive technology co-developed by CEO Liang Qiao, an associate professor at Loyola University Chicago's Strich School of Medicine, targets infection in mucosal tissues, the first type of tissue attacked by HIV. The Chinese government, mindful of the rapid expansion of AIDS in China has, through the "Green Mile Policy" acted to expedite the approval of domestically produced HIV Vaccines and has dramatically increased its spending on AIDS-related research. In accordance with this policy, Bio-Bridge expects to bring its therapeutic HIV Vaccine to market as early as 2008, far in advance of many other HIV Vaccines currently in development. Bio-Bridge is currently constructing a new $3 million state-of-the-art GMP research and manufacturing facility in Beijing, which is expected to be completed by the end of this year.